The size of the Urinary Tract Infections Market in the Asia Pacific was worth USD 4.03 billion in 2020 and estimated to be growing at a CAGR of 2.46%, to reach USD 4.55 billion by 2025.
Urinary Tract Infection is an infection which affects parts of the urinary tract. When it affects the lower urinary tract it is called as a bladder infection or cystitis and when it affects the upper urinary tract it is called kidney infection or pyelonephritis. Symptoms from a lower urinary tract include frequent urination, pain with urination, and feeling the need to urinate in spite of having an empty bladder. Symptoms of a kidney infection include flank pain and fever usually in addition to the symptoms of a lower urinary tract infection. The urine may appear bloody in rare cases. In the very young and the very old, symptoms may be non-specific or vague.
The most common cause of infection is E coli, though other fungi or bacteria may rarely might be the cause. Risk factors include female anatomy, diabetes, obesity, sexual intercourse, and family history. Although sexual intercourse is a risk factor, urinary tract infections are not categorized as sexually transmitted infections. If kidney infection occurs, it usually follows a bladder infection but can also result from infection which is blood-borne in nature. Diagnosis in young healthy women can be based alone on symptoms. In those with vague symptoms, diagnosis is difficult since bacteria may be present without infection being present. In complicated cases or when conventional treatments fail, a urine culture may be useful.
The driving factors of Asia Pacific urinary tract infections market are sudden rise in the prevalence rate and the diagnosis for the disease. This has started the opportunities for major players to allocate their resources towards research and development of a combination therapy. This will surely result in the growth of market size during the forecast period. With the launch of new drugs for multiple indications under urinary tract infections, and label expansion for drugs which are already existing, the market is expected to boost further. The generic, low cost competition for some of the drugs is fierce and is forecasted to get more competitive and thus can contribute to offsetting of the figures for current market size.
This research report on the APAC Urinary Tract Infections Market has been segmented and sub-segmented into the following categories:
By Type of Medication:
By Type of Indication:
Regionally, Asia Pacific has the largest market in the world for urinary tract infections by share, and is also the fastest growing region. Factors such as increasing geriatric population and growing disposable incomes are expected to propel the market growth in the region.
Noteworthy companies dominating the Asia Pacific Urinary Tract Infections market profiled in this report are Pfizer, Inc., AstraZeneca plc, Johnson & Johnson, Novartis International AG., F. Hoffmann La Roche Ltd., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim GmbH, and Cipla Ltd., among others.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Type of Medication
5.1.1 Penicillin & Combinations
18.104.22.168 Amoxicillin-Clavulanate Potassium combination
22.214.171.124 Nalidixic Acid
126.96.36.199 Trimethoprim combination
5.1.6 Azoles & Amphotericin B
5.1.9 Y-o-Y Growth Analysis, By Type of Medication
5.1.10 Market Attractiveness Analysis, By Type of Medication
5.1.11 Market Share Analysis, By Type of Medication
5.2 Type of Indication
5.2.1 Uncomplicated UTI
5.2.2 Complicated UTI
5.2.3 Recurring Complicated UTI
5.2.4 Neurogenic Bladder Infection
5.2.5 Y-o-Y Growth Analysis, By Type of Indication
5.2.6 Market Attractiveness Analysis, By Type of Indication
5.2.7 Market Share Analysis, By Type of Indication
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
188.8.131.52 By Type of Medication
184.108.40.206 By Type of Indication
6.1.4 Market Attractiveness Analysis
220.127.116.11 By Type of Medication
18.104.22.168 By Type of Indication
6.1.5 Market Share Analysis
22.214.171.124 By Type of Medication
126.96.36.199 By Type of Indication
6.5 South Korea
7. Strategic Analysis
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Pfizer, Inc.
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 AstraZeneca plc
8.3 Johnson & Johnson
8.4 Novartis International AG.
8.5 F. Hoffmann La Roche Ltd.
8.6 Teva Pharmaceutical Industries Ltd.
8.7 Boehringer Ingelheim GmbH
8.8 Cipla Ltd.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures